Omega-3 fatty acids improve quality of life, outcomes in cancer

the ONA take:

According to a new study published online ahead of print in the Journal of Parenteral and Enteral Nutrition (JPEN), researchers at the University Hospitals of Leicester in the United Kingdom have found that the addition of omega-3 fatty acids to anti-cancer medications may improve quality of life and treatment outcomes in patients with cancer.

For the study, researchers enrolled 150 patients with advanced pancreatic cancer. Participants received gemcitabine 1,000 mg weekly followed by up to 100 g of omega-3 rich lipid emulsion for 3 weeks followed by 1 rest week. Patients received up to six cycles until disease progression, unacceptable toxicity, patient request, or death.

Results showed that patients who received omega-3 fatty acids experienced an improvement in response activity and disease stabilization rates, a reduction in liver metastases volume, and improved quality of life.

The findings suggest that further investigation is warranted to evaluate the addition of omega-3 fatty acids with a chemotherapy agent in a randomized phase III trial.

Omega-3 fatty acids may inhibit prostate cancer cell growth
Addition of omega-3 fatty acids to anti-cancer medications may improve quality of life and treatment outcomes in patients with cancer.
Adding omega-3 fatty acids to anti-tumor medications may improve treatment response and quality of life for cancer patients according to a new study by researchers at the University Hospitals of Leicester in the United Kingdom.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs